Alzheimer's Therapy Drug: Should We Pay $56,000 to Slow the Loss of Mom's Mind?
2 years ago
1.04K
Aduhelm sparks controversy as a therapy drug for Alzheimer's patients that attacks amyloid plaques in the brain, and slows the decline of memory and problem-solving by about 25% over time. It's not a cure, and it can't even restore lost mental capabilities. Now that the FDA has fast-tracked approval, should American taxpayers cover the $56,000/year per patient cost for relative minor results?
Scott Ott, Stephen Green and Bill Whittle create 240 new episodes of Right Angle annually, thanks to our Members. Join us now at https://BillWhittle.com
Loading 19 comments...
-
21:05
Bill Whittle: Conservative Opinion | Humor
14 days ago $3.04 earnedThis is NPR
2.58K15 -
1:21:51
TheDAMpodcast
3 years ago $0.06 earnedWhen and why should anyone take therapy?
911 -
3:56
NEWSMAX
2 years agoFDA APPROVES NEW ALZHEIMER'S DRUG
1.9K23 -
1:11
IOL-IndependentOnline
2 years ago $0.01 earnedFirst patient receives controversial Biogen Alzheimer's drug
32 -
1:56
KGUN
2 years agoHikers should keep heat safety in mind
2 -
40:20
Stephen Gardner
3 hours ago🔴Biden just announced the UNTHINKABLE!
29K37 -
LIVE
Tommy's Podcast
4 hours agoE452: Crobble Dra Grum
374 watching -
1:24:03
Dr. Drew
8 hours agoTurbo Cancer & mRNA: Dr. Peter McCullough Warns of Rising Rate of Cancer Genesis w/ Dave Rubin & Steph Coulson – Ask Dr. Drew
51.6K69 -
1:29:38
Redacted News
8 hours agoOh SH*T! It's All COLLAPSING and They Can't Stop It, Putin Warns West
113K324 -
1:39:35
Megyn Kelly
6 hours agoJudge Violates Trump's Free Speech, and What Noem's Lies Expose, w/ Vivek Ramaswamy and Buck Sexton
56.3K69